Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + clonidine is a local anesthetic combination formulation investigated for intraoral anesthesia, particularly in patients with type 2 diabetes mellitus (DMT2). It consists of 2% lidocaine, a voltage-gated sodium channel blocker, and 15 mcg/mL clonidine, an alpha-2 adrenergic receptor agonist. In this formulation, clonidine acts as a vasoconstrictor and analgesic adjuvant, serving as an alternative to epinephrine. Research conducted by the University of Belgrade suggests that this combination provides effective anesthesia for dental procedures like tooth extractions while maintaining stable cardiovascular parameters, making it a potentially safer option for patients with cardiovascular concerns or diabetes compared to traditional lidocaine-epinephrine mixtures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + clonidine.